Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27
Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.
Stocks · News reference
BridgeBio Oncology shares are trading lower after Leerink Partners lowered its price target on the stock from $39 to $27.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20
Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.